304 related articles for article (PubMed ID: 30501012)
21. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP).
Kaplan FS; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():158-161. PubMed ID: 28600150
[TBL] [Abstract][Full Text] [Related]
23. Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva.
Burdick LN; DelVichio AH; Hanson LR; Griffith BB; Bouchard KR; Hunter JW; Goldhamer DJ
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397414
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva.
Ullrich T; Arista L; Weiler S; Teixeira-Fouchard S; Broennimann V; Stiefl N; Head V; Kramer I; Guth S
Bioorg Med Chem Lett; 2022 May; 64():128667. PubMed ID: 35276359
[TBL] [Abstract][Full Text] [Related]
25. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Chakkalakal SA; Shore EM
Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
[TBL] [Abstract][Full Text] [Related]
26. Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP).
Lindborg CM; Brennan TA; Wang H; Kaplan FS; Pignolo RJ
Bone; 2018 Apr; 109():153-157. PubMed ID: 28963080
[TBL] [Abstract][Full Text] [Related]
27. BMP type I receptor inhibition reduces heterotopic [corrected] ossification.
Yu PB; Deng DY; Lai CS; Hong CC; Cuny GD; Bouxsein ML; Hong DW; McManus PM; Katagiri T; Sachidanandan C; Kamiya N; Fukuda T; Mishina Y; Peterson RT; Bloch KD
Nat Med; 2008 Dec; 14(12):1363-9. PubMed ID: 19029982
[TBL] [Abstract][Full Text] [Related]
28. Fibrodysplasia ossificans progressiva. A case report and focus on the BMP signaling pathway.
Bouvard B; Masson C; Legrand E; Audran M
Morphologie; 2016 Dec; 100(331):250-255. PubMed ID: 26948676
[TBL] [Abstract][Full Text] [Related]
29. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva.
Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K
Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611
[TBL] [Abstract][Full Text] [Related]
30. Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable.
Al Mukaddam M; Rajapakse CS; Pignolo RJ; Kaplan FS; Smith SE
Bone; 2018 Apr; 109():147-152. PubMed ID: 28822792
[TBL] [Abstract][Full Text] [Related]
31. Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.
Matsuo K; Chavez RD; Barruet E; Hsiao EC
Curr Osteoporos Rep; 2019 Dec; 17(6):387-394. PubMed ID: 31721068
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic treatment of rapamycin ameliorates naturally developing and episode -induced heterotopic ossification in mice expressing human mutant ACVR1.
Maekawa H; Kawai S; Nishio M; Nagata S; Jin Y; Yoshitomi H; Matsuda S; Toguchida J
Orphanet J Rare Dis; 2020 May; 15(1):122. PubMed ID: 32448372
[TBL] [Abstract][Full Text] [Related]
33. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
Luo Y; Alsamarah A; Zhang K; Hao J
Curr Mol Med; 2016; 16(1):4-11. PubMed ID: 26695699
[TBL] [Abstract][Full Text] [Related]
34. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP).
Kaplan FS; Al Mukaddam M; Pignolo RJ
Bone; 2017 Aug; 101():123-128. PubMed ID: 28465250
[TBL] [Abstract][Full Text] [Related]
35. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
Lin H; Shi F; Gao J; Hua P
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
[TBL] [Abstract][Full Text] [Related]
36. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
[TBL] [Abstract][Full Text] [Related]
37. Modeling the
Barruet E; Garcia SM; Wu J; Morales BM; Tamaki S; Moody T; Pomerantz JH; Hsiao EC
Elife; 2021 Nov; 10():. PubMed ID: 34755602
[TBL] [Abstract][Full Text] [Related]
38. Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.
Goldhamer DJ; Lees-Shepard JB
Elife; 2019 Jan; 8():. PubMed ID: 30698142
[TBL] [Abstract][Full Text] [Related]
39. Immunologic Aspects in Fibrodysplasia Ossificans Progressiva.
Diolintzi A; Pervin MS; Hsiao EC
Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540775
[TBL] [Abstract][Full Text] [Related]
40. [Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva].
Katagiri T; Kamizono J; Nakashima Y; Kitoh H; Susami T; Haga N
Clin Calcium; 2010 Oct; 20(10):1510-7. PubMed ID: 20890033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
